| scholarly article | Q13442814 |
| P356 | DOI | 10.1016/S0002-9149(96)00159-2 |
| P698 | PubMed publication ID | 8651092 |
| P2093 | author name string | G Assmann | |
| H Schulte | |||
| A von Eckardstein | |||
| P2860 | cites work | Triglyceride-rich lipoproteins and the progression of coronary artery disease | Q40479984 |
| Lipoprotein (a) and coronary heart disease. | Q40479993 | ||
| Quantitation of plasma apolipoproteins in the primary and secondary prevention of coronary artery disease | Q40753215 | ||
| A prospective study of lipoprotein(a) and the risk of myocardial infarction | Q41061586 | ||
| Lipoprotein (a) and coronary heart disease risk: a nested case-control study of the Helsinki Heart Study participants | Q41148759 | ||
| Low-Density Lipoprotein Subclass Patterns and Risk of Myocardial Infarction | Q44144342 | ||
| Triglyceride-rich lipoproteins isolated by selected-affinity anti-apolipoprotein B immunosorption from human atherosclerotic plaque. | Q44759552 | ||
| Plasma triglyceride level and mortality from coronary heart disease | Q46688316 | ||
| Lipoprotein Lp(a) as predictor of myocardial infarction in comparison to fibrinogen, LDL cholesterol and other risk factors: results from the prospective Göttingen Risk Incidence and Prevalence Study (GRIPS). | Q48754609 | ||
| Relation of fasting plasma insulin concentration to high density lipoprotein cholesterol and triglyceride concentrations in men. | Q51608661 | ||
| Joint effects of serum triglyceride and LDL cholesterol and HDL cholesterol concentrations on coronary heart disease risk in the Helsinki Heart Study. Implications for treatment | Q67720940 | ||
| Relation of high-density lipoprotein cholesterol and triglycerides to incidence of atherosclerotic coronary artery disease (the PROCAM experience). Prospective Cardiovascular Münster study | Q68037615 | ||
| Predictive value of apolipoproteins in a prospective survey of coronary artery disease in men | Q68125221 | ||
| Risk factors in middle age that predict early and late onset of coronary heart disease | Q69949126 | ||
| Apolipoproteins and ischaemic heart disease: implications for screening | Q72662515 | ||
| P433 | issue | 14 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | hypertriglyceridemia | Q1467339 |
| P304 | page(s) | 1179-1184 | |
| P577 | publication date | 1996-06-01 | |
| P1433 | published in | American Journal of Cardiology | Q2208417 |
| P1476 | title | Hypertriglyceridemia and elevated lipoprotein(a) are risk factors for major coronary events in middle-aged men | |
| P478 | volume | 77 |
| Q47987286 | A controlled trial of the effects of pattern of alcohol intake on serum lipid levels in regular drinkers |
| Q39703989 | A hypertriglyceridemic state increases high sensitivity C-reactive protein of Japanese men with normal glucose tolerance |
| Q24294901 | A zinc finger HIT domain-containing protein, ZNHIT-1, interacts with orphan nuclear hormone receptor Rev-erbbeta and removes Rev-erbbeta-induced inhibition of apoCIII transcription |
| Q46763309 | Ankle-arm blood pressure monitoring does not correlate with serum lipoprotein a in renal transplant recipients |
| Q35172672 | Appropriateness of cholesterol and triglycerides reporting checked by External Quality Assessment programs. |
| Q43758804 | Association of serum apolipoprotein A-I (but not high-density lipoprotein cholesterol) with healed myocardial infarction in men independent of serum insulin and C-peptide |
| Q41454232 | Atorvastatin. A review of its pharmacology and therapeutic potential in the management of hyperlipidaemias |
| Q50936891 | Basal growth hormone levels are positively correlated with high-density lipoprotein cholesterol levels in women. |
| Q33843624 | Cardiovascular disease in diabetic patients |
| Q36161379 | Cardiovascular disease risk factors in Ghana during the rural-to-urban transition: A cross-sectional study |
| Q37789792 | Cardiovascular effects of edible oils: a comparison between four popular edible oils. |
| Q45224087 | Cholesterolemia control in Spain, 2000: a tool for cardiovascular disease prevention |
| Q73965127 | Clinical implications of elevated lipoprotein(a) |
| Q33646070 | Clinical positioning of HMG-CoA reductase inhibitors in lipid management protocols |
| Q34327226 | Combination lipid-altering therapy: an emerging treatment paradigm for the 21st century |
| Q30434678 | Combination therapy of dyslipidemia in non-insulin-dependent diabetes mellitus and the metabolic syndrome. |
| Q25257849 | Comparison of isocaloric very low carbohydrate/high saturated fat and high carbohydrate/low saturated fat diets on body composition and cardiovascular risk |
| Q24798033 | Consistency of genetic inheritance mode and heritability patterns of triglyceride vs. high density lipoprotein cholesterol ratio in two Taiwanese family samples |
| Q36633470 | Convergent evolution of apolipoprotein(a) in primates and hedgehog |
| Q35734015 | Cost effectiveness of combination therapy with pioglitazone for type 2 diabetes mellitus from a german statutory healthcare perspective |
| Q73575756 | Detection of missense mutations in the genes for lipoprotein lipase and hepatic triglyceride lipase in patients with dyslipidemia undergoing coronary angiography |
| Q26750905 | Diabetes Dyslipidemia |
| Q33712893 | Differences in DBA/1J and DBA/2J reveal lipid QTL genes |
| Q64068806 | Distribution and Characteristics of Hypouricemia within the Japanese General Population: A Cross-Sectional Study |
| Q62661500 | Does Lipoprotein(a) Impair Endothelial Function? |
| Q33781938 | Does abdominal obesity accelerate the effect of hypertriglyceridemia on impaired fasting glucose? |
| Q46918945 | Dose-dependent effects of docosahexaenoic acid-rich fish oil on erythrocyte docosahexaenoic acid and blood lipid levels |
| Q59913879 | Dose-dependent increases in heart rate variability and arterial compliance in overweight and obese adults with DHA-rich fish oil supplementation |
| Q37334006 | Effect of TAK-085 on Low-density Lipoprotein Particle Size in Patients with Hypertriglyceridemia: A Double-blind Randomized Clinical Study |
| Q38773916 | Effect of hypercholesterolaemia on myocardial function, ischaemia-reperfusion injury and cardioprotection by preconditioning, postconditioning and remote conditioning |
| Q43557302 | Effect of orlistat-assisted weight loss in decreasing coronary heart disease risk in patients with syndrome X. |
| Q28196423 | Effect of xuezhikang, a cholestin extract, on reflecting postprandial triglyceridemia after a high-fat meal in patients with coronary heart disease |
| Q50236094 | Effects of improved fat meat products consumption on emergent cardiovascular disease markers of male volunteers at cardiovascular risk. |
| Q74530447 | Elevated plasma lipoprotein(a) is associated with coronary artery disease in patients with chronic stable angina pectoris |
| Q46862147 | Epidemiology of the metabolic syndrome in 2045 French military personnel (EPIMIL study). |
| Q35170825 | Established and recently identified coronary heart disease risk factors in young people: the influence of physical activity and physical fitness |
| Q34071541 | Evidence that triglycerides are an independent coronary heart disease risk factor |
| Q40070894 | Factors associated with high cardiovascular risk in a primarily African American, urban HIV-infected population. |
| Q36012834 | Fasting serum triglyceride and high-density lipoprotein cholesterol levels in patients intended to be treated for dyslipidemia |
| Q28284661 | Fenofibric acid: a new fibrate approved for use in combination with statin for the treatment of mixed dyslipidemia |
| Q36527433 | Fibrinogen deficiency reduces vascular accumulation of apolipoprotein(a) and development of atherosclerosis in apolipoprotein(a) transgenic mice |
| Q33680333 | HDL lipid composition is profoundly altered in patients with type 2 diabetes and atherosclerotic vascular disease. |
| Q45949323 | High carbohydrate diets, triglyceride-rich lipoproteins, and coronary heart disease risk. |
| Q33746611 | High risk strategies for atherosclerosis |
| Q34327242 | Hormone replacement therapy for prevention of coronary heart disease: current evidence |
| Q71656243 | Hypertriglyceridemia and elevated lipoprotein(a) are major risk factors for coronary events in middle-aged men |
| Q44268486 | Hypertriglyceridemia as a cardiovascular risk factor |
| Q55176268 | Hypertriglyceridemia in Diabetes Mellitus: Implications for Pediatric Care. |
| Q34687470 | Hypertriglyceridemia: a too long unfairly neglected major cardiovascular risk factor |
| Q33652012 | Hypertriglyceridemia: changes in the plasma lipoproteins associated with an increased risk of cardiovascular disease |
| Q73887951 | Hypertriglyceridemia: new insights and new approaches to pharmacologic therapy |
| Q47422605 | Identification and Characterization of Fenofibrate-Induced Liver Injury |
| Q34027319 | Identification and treatment of hypertriglyceridemia as a risk factor for coronary heart disease |
| Q33646056 | Impact of dyslipidaemia. Lessons from clinical trials |
| Q43672380 | Impact of lipid abnormalities in development and progression of transplant coronary disease: a serial intravascular ultrasound study |
| Q31123022 | Impact of multiple cardiovascular risk factors on carotid intima-media thickness and elasticity |
| Q28596181 | Impaired lipid levels and inflammatory response in rats exposed to cadmium |
| Q35263542 | Influence of genetic variants in the apolipoprotein A5 and C3 gene on lipids, lipoproteins, and its association with coronary artery disease in Indians |
| Q54348266 | Involvement of RBP4 in hyperinsulinism-induced vascular smooth muscle cell proliferation. |
| Q44179973 | Is arterial hypertension an underlying factor in the increased serum Lp(a) levels in ESRD dialyzed patients? |
| Q44583853 | LDL phenotype B and other lipid abnormalities in patients with large vessel disease and small vessel disease |
| Q50651579 | Laboratory-based calculation of coronary heart disease risk in a hospital diabetic clinic. |
| Q30242031 | Lipoprotein (a) as a cause of cardiovascular disease: insights from epidemiology, genetics, and biology |
| Q34647728 | Lipoprotein (a) as a predictor of coronary heart disease: the PRIME Study |
| Q31817214 | Lipoprotein (a) as a predictor of myocardial infarction in middle-aged men. |
| Q43729975 | Lipoprotein (a) level in the population in Taiwan: relationship to sociodemographic and atherosclerotic risk factors |
| Q44179968 | Lipoprotein abnormalities in hemodialysis and continuous ambulatory peritoneal dialysis patients |
| Q77910775 | Lipoprotein lipase greatly enhances the retention of lipoprotein(a) to endothelial cell-matrix |
| Q43762325 | Lipoprotein(a) as a risk factor for maternal cardiovascular disease mortality in kindreds with familial combined hyperlipidemia or familial hypertriglyceridemia |
| Q35737842 | Lipoprotein(a) concentration and the risk of coronary heart disease, stroke, and nonvascular mortality |
| Q32054940 | Lipoprotein(a) further increases the risk of coronary events in men with high global cardiovascular risk |
| Q43906733 | Lipoprotein(a) in American Indians is low and not independently associated with cardiovascular disease. The Strong Heart Study |
| Q21284797 | Lipoprotein(a) in cardiovascular diseases |
| Q77714432 | Lipoprotein(a) interactions with lipid and non-lipid risk factors in patients with early onset coronary artery disease: results from the NHLBI Family Heart Study |
| Q24629580 | Lipoprotein(a), hormone replacement therapy, and risk of future cardiovascular events |
| Q91684402 | Lipoprotein(a): An independent, genetic, and causal factor for cardiovascular disease and acute myocardial infarction |
| Q90204365 | Lipoprotein(a): An underrecognized genetic risk factor for malignant coronary artery disease in young Indians |
| Q52603648 | Long-Term Intermittent Work at High Altitude: Right Heart Functional and Morphological Status and Associated Cardiometabolic Factors. |
| Q74315464 | Low apolipoprotein A-IV plasma concentrations in men with coronary artery disease |
| Q34766053 | Low-carbohydrate diets, obesity, and metabolic risk factors for cardiovascular disease |
| Q34340167 | Lower serum triglyceride level is a risk factor for in-hospital and late major adverse events in patients with ST-segment elevation myocardial infarction treated with primary percutaneous coronary intervention- a cohort study. |
| Q50099270 | Magnolol-mediated regulation of plasma triglyceride through affecting lipoprotein lipase activity in apolipoprotein A5 knock-in mice |
| Q35101119 | Management of patients with diabetic hyperlipidemia |
| Q35826088 | Meta-analysis of large randomized controlled trials to evaluate the impact of statins on cardiovascular outcomes |
| Q37370315 | Modification of apolipoprotein(a) lysine binding site reduces atherosclerosis in transgenic mice |
| Q39344281 | Moringa oleifera Leaf Extract: Beneficial Effects on Cadmium Induced Toxicities - A Review |
| Q74823705 | New concepts and paradigms in cardiovascular medicine: the noninvasive management of coronary artery disease |
| Q36300187 | Obesity and lipids |
| Q34129395 | Orphan nuclear hormone receptor Rev-erbalpha regulates the human apolipoprotein CIII promoter |
| Q37253787 | Pathologic findings in rabbit models of hereditary hypertriglyceridemia and hereditary postprandial hypertriglyceridemia. |
| Q40016570 | Phosphorylation of liver X receptor alpha selectively regulates target gene expression in macrophages |
| Q34107425 | Postprandial lipemia and coronary risk |
| Q35495455 | Prevalence of dyslipidemia in patients receiving health checkups: a hospital-based study |
| Q46249438 | Prevalence of emerging cardiovascular risk factors in younger individuals with a family history of premature coronary heart disease and low Framingham risk score. |
| Q34003407 | Preventing, stopping, or reversing coronary artery disease--triglyceride-rich lipoproteins and associated lipoprotein and metabolic abnormalities: the need for recognition and treatment |
| Q90467118 | Prevention of Cardiovascular Events with Omega-3 Polyunsaturated Fatty Acids and the Mechanism Involved |
| Q77714696 | Prevention of coronary heart disease in clinical practice: recommendations of the Second Joint Task Force of European and other Societies on Coronary Prevention |
| Q34188848 | Pro and con: high-density lipoprotein, triglycerides, and other lipid subfractions are the future of lipid management |
| Q31879006 | Prospective association of lipoprotein(a) concentrations and apo(a) size with coronary heart disease among men in the Multiple Risk Factor Intervention Trial |
| Q34398826 | Regression-based association analysis with clustered haplotypes through use of genotypes. |
| Q44064917 | Regulation of small dense LDL concentration in Korean and Scottish men and women |
| Q74147884 | Relation between lipoprotein (a) and in vitro oxidation of apolipoprotein B-containing lipoproteins |
| Q44109222 | Relationship between plasma leptin levels and lipid profiles among school children in Taiwan--the Taipei Children Heart Study. |
| Q51559550 | Relationship between triglycerides and factor VIIc and plasminogen activator inhibitor type-1: lack of threshold value. |
| Q33646061 | Resource utilisation in the management of dyslipidaemia |
| Q78004675 | Sequence polymorphisms in the apolipoprotein(a) gene and their association with lipoprotein(a) levels and myocardial infarction. The ECTIM Study |
| Q36766879 | Serum pigment epithelium-derived factor levels are independently correlated with the presence of coronary artery disease |
| Q28369047 | Statin + fibrate combination therapy fluvastatin with bezafibrate or ciprofibrate in high risk patients with vascular disease |
| Q27010638 | Statins in cardiometabolic disease: what makes pitavastatin different? |
| Q60311710 | Structure of human CD1b with bound ligands at 2.3 Å, a maze for alkyl chains |
| Q45778627 | Study of molecular mechanism of Prostaglandin E1 in inhibiting coronary heart disease |
| Q35861948 | The High Prevalence of Low HDL-Cholesterol Levels and Dyslipidemia in Rural Populations in Northwestern China |
| Q28199120 | The Human Apolipoprotein AV Gene Is Regulated by Peroxisome Proliferator-activated Receptor-α and Contains a Novel Farnesoid X-activated Receptor Response Element |
| Q47739578 | The atherogenic lipoprotein phenotype and vascular endothelial dysfunction |
| Q42758199 | The end of triglycerides in cardiovascular risk assessment?. Rumours of death are greatly exaggerated |
| Q33665230 | The epidemiology of triglyceride as a coronary artery disease risk factor |
| Q37167521 | The independent relationship between triglycerides and coronary heart disease. |
| Q24300197 | The orphan nuclear receptor Rev-erbbeta recruits Tip60 and HDAC1 to regulate apolipoprotein CIII promoter |
| Q26749317 | The relationship between Lp(a) and CVD outcomes: a systematic review |
| Q37296213 | The relationship between physical fitness and coronary risk factor profiles in Japanese women |
| Q37308002 | The role of triglycerides in cardiovascular risk |
| Q33752800 | The treatment of hypertension and dyslipidemia in diabetes mellitus |
| Q73919585 | Treatment goals for low-density lipoprotein cholesterol in the secondary prevention of coronary heart disease: absolute levels or extent of lowering? |
| Q73228446 | Treatment of hypertriglyceridemia by two diets rich either in unsaturated fatty acids or in carbohydrates: effects on lipoprotein subclasses, lipolytic enzymes, lipid transfer proteins, insulin and leptin |
| Q51566825 | Triglyceride as a risk factor for coronary artery disease. |
| Q73370415 | Usefulness of hypertriglyceridemia in predicting myocardial infarction late after coronary artery bypass operation |
| Q36684192 | Will torcetrapib be the next big thing in coronary heart disease risk reduction? |
| Q74178835 | [Control of cholesterolemia in Spain, 2000. A tool for cardiovascular prevention] |
| Q74219044 | [Guidelines of the Spanish Society of Cardiology for cardiovascular disease prevention and cardiac rehabilitation] |
| Q73126824 | [Hypertriglyceridemia as a cardiovascular risk factor. The end of a controversy?] |
| Q57658275 | Évaluation du risque cardiovasculaire |
Search more.